<DOC>
	<DOCNO>NCT00171730</DOCNO>
	<brief_summary>Acromegaly rare , serious condition characterize chronic hypersecretion growth hormone ( GH ) , generally cause GH-secreting pituitary adenoma . This study assess long-term safety efficacy pasireotide patient acromegaly .</brief_summary>
	<brief_title>An Extension Study Assess Long-term Safety Efficacy Pasireotide Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Patients complete four treatment regimen core study CSOM230B2201 achieve biochemical control GH IGF1 level least one month pasireotide administration three dose Patients experience unacceptable adverse event tolerability issue core study CSOM230B2201 Patients experience developed compression optic chiasm cause visual field defect core study CSOM230B2201 Patients require surgical intervention relief sign symptom associate tumor compression core study CSOM230B2201 Patients experience developed congestive heart failure , unstable angina , sustain ventricular tachycardia , ventricular fibrillation acute myocardial infraction core study CSOM230B2201 Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Pasireotide</keyword>
	<keyword>GH</keyword>
	<keyword>IGF-1</keyword>
</DOC>